Data looking better for CTI's blood cancer drug tosedostat
This article was originally published in Scrip
Executive Summary
In a Phase II investigator-sponsored study focused on the elderly, CTI BioPharma's acute myeloid leukemia (AML) therapy tosedostat has seen almost half of patients achieve durable complete responses.